NANBIOSIS takes part in a key S4i 2026 round table on science–industry collaboration, highlighting Spain’s science industry and technology transfer.
Madrid, February 2026 — Last week, NANBIOSIS contributed to a high-level round table at Science for Industry (S4i) 2026, an event focused on strengthening a knowledge-based economic model and accelerating the commercialization of scientific advances to boost competitiveness in Europe.
S4i 2026 advocates for high-value reindustrialization driven by science, emphasizing the transformative potential of Deep Science to foster innovation, safeguard future growth, and catalyze a significant upturn in the EU economy by shortening the path from research to market.
Round table: Science industry in Spain and the connection between research and innovation
The round table, titled “Science industry in Spain and the connection between research and innovation” explored the role and potential of the Spanish science industry ecosystem. The session brought together representatives from public administration, industry, and national research infrastructures to discuss how collaboration can promote innovation, enhance technology transfer, and create new opportunities across sectors.
Participants provided insights into current dynamics between science and industry, the specificities of the science industry market, emerging business models at the science–industry interface, and the success factors for deep tech spin-offs—particularly in biotechnology, ICT, health, and energy.
Speakers
- Amparo López, Member of the SOMMa Executive Committee and Delegate of the SOMMa Knowledge Transfer and Innovation Working Group
- Manuel Espinosa, General Manager at DEMEDE Engineering; Engineer & MBA with extensive experience in technology transfer, product design, and deep tech entrepreneurship
- Leonor Mendoza, Head of Collaborative Projects at INEUSTAR, the Spanish Science Industry Association
- Gabriel Alfranca, Head of Communications at NANBIOSIS, the Research Infrastructure in Nanomaterials, Biomaterials and Systems in Biomedicine
The roundtable was originally scheduled to be chaired by Javier Echávarri Delmás, National Industry Liaison Officer for Astronomy and Particle Physics at CDTI, who was ultimately unable to attend due to health reasons. The chair was therefore assumed by Leonor Mendoza.
Session structure and key topics
The session included an introduction and speaker presentations, followed by a moderated panel discussion addressing:
- The mutual dependence of science and industry and current collaboration dynamics in Spain.
- What differentiates the science industry market and why it represents a strategic opportunity for companies.
- New business models emerging at the science–industry crossroads, including drivers and challenges, in which NANBIOSIS plays a key role.
- Critical considerations for the success of deep tech spin-offs originating from scientific research.
By contributing to this round table at S4i 2026, NANBIOSIS reinforces its commitment to fostering collaboration between research infrastructures and industry, supporting technology transfer, and advancing innovation in nanomedicine and biomedicine within the Spanish and European ecosystems.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
If you want to collaborate with us, visit our Order Request page.
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
